Adrian Rawcliffe, CEO: Adaptimmune Therapeutics ADAPY Sell · Filed 24/01/12

Trade details

Type: Insider sale
Amount: $14,668.45
Shares · price: 17,257 sh · $0.85 a share
Held after: 26,388 sh
Stock: Adaptimmune Therapeutics ADAPY
Person: Adrian RawcliffeCEO
Trade date: 24/01/12
Filed: 24/01/12
Days to filing: 0 days

Sold 39.5% of holdings

Share of holding sold: 39.5%

Adaptimmune Therapeutics trades, last 26 weeks

What else happened in Adaptimmune Therapeutics around then

Filed or reported within 30 days of the trade day · 23/12/13~24/02/11

Adrian Rawcliffe's recent trades

Adrian RawcliffeDirector
Planned sale10b5-1 planWave Life Sciences
Planned sale10b5-1 plan
Wave Life Sciences
WVE
$64.1K
12,700 sh
$64.1K
Filed 08/12
Traded 08/12
Adrian RawcliffeDirector
Sell10b5-1 planWave Life Sciences
Sell10b5-1 plan
Wave Life Sciences
WVE
$630K
42,000 sh
$630K
Filed 25/12/10
Traded 25/12/08
Adrian RawcliffeDirector
Planned sale10b5-1 planWave Life Sciences
Planned sale10b5-1 plan
Wave Life Sciences
WVE
$314.6K
42,000 sh
$314.6K
Filed 25/12/08
Traded 25/12/08
Adrian RawcliffeDirector
Sell10b5-1 planWave Life Sciences
Sell10b5-1 plan
Wave Life Sciences
WVE
$109.4K
16,115 sh
$109.4K
Filed 25/11/14
Traded 25/11/13
Adrian RawcliffeDirector
Planned sale10b5-1 planWave Life Sciences
Planned sale10b5-1 plan
Wave Life Sciences
WVE
$112.1K
16,115 sh
$112.1K
Filed 25/11/13
Traded 25/11/13

Adrian Rawcliffe, CEO — sold $14.7K of Adaptimmune Therapeutics ADAPY · 39.5% of holdings | Whalegun